Coronavirus Update: 'Positive News' Imminent From Oxford and AstraZeneca Vaccine
Plus: Favipiravir Price Cut And New Approval In India
More news from across the sector, including Novartis's non-profit pledge on medicines and Zydus Cadila commencing Phase I vaccine trial.
You may also be interested in...
Disappointment as Roche/Chugai antibody tocilizumab misses most endpoints.
Executives from Moderna, Pfizer and AstraZeneca and others will give politicians in Washington DC an update on the progress of their vaccine - but will resist pressure to make promises of a breakthrough in 2020.
Experience from previous viral outbreaks has allowed the UK agency to move quickly; long-term focus is on hybrid inspection approach.